Pharma Deals Review, Vol 2010, No 8 (2010)

Font Size:  Small  Medium  Large

Novartis Acquires Option to Phase II siRNA Drug from Quark Pharmaceuticals

Heather Cartwright

Abstract


Quark Pharmaceuticals has granted Novartis an option to license QPI-1002, a drug for acute kidney injury that is currently in Phase II, in a deal that could be worth US$670 M. QPI-1002 is the first siRNA therapeutic to be administered systemically to humans.



Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.